CO7160087A2 - Nalmefeno para reducir el consumo de alcohol en poblaciones diana específicas - Google Patents

Nalmefeno para reducir el consumo de alcohol en poblaciones diana específicas

Info

Publication number
CO7160087A2
CO7160087A2 CO14280546A CO14280546A CO7160087A2 CO 7160087 A2 CO7160087 A2 CO 7160087A2 CO 14280546 A CO14280546 A CO 14280546A CO 14280546 A CO14280546 A CO 14280546A CO 7160087 A2 CO7160087 A2 CO 7160087A2
Authority
CO
Colombia
Prior art keywords
nalmefene
alcohol consumption
specific target
target populations
reduce alcohol
Prior art date
Application number
CO14280546A
Other languages
English (en)
Spanish (es)
Inventor
Lars Torup
Afsaneh Abbariki
Anna Bladström
Christine Persson
Didier Meulien
Per Sorensen
Thomas Jon Jensen
Jette Buch Ostergaard
Original Assignee
Lundbeck & Co As H
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48703496&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO7160087(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lundbeck & Co As H filed Critical Lundbeck & Co As H
Publication of CO7160087A2 publication Critical patent/CO7160087A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Addiction (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
CO14280546A 2012-06-27 2014-12-22 Nalmefeno para reducir el consumo de alcohol en poblaciones diana específicas CO7160087A2 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201261664804P 2012-06-27 2012-06-27
US201261721539P 2012-11-02 2012-11-02
US201261736740P 2012-12-13 2012-12-13
US201361788810P 2013-03-15 2013-03-15

Publications (1)

Publication Number Publication Date
CO7160087A2 true CO7160087A2 (es) 2015-01-15

Family

ID=48703496

Family Applications (1)

Application Number Title Priority Date Filing Date
CO14280546A CO7160087A2 (es) 2012-06-27 2014-12-22 Nalmefeno para reducir el consumo de alcohol en poblaciones diana específicas

Country Status (35)

Country Link
US (4) US20140005217A1 (enExample)
EP (5) EP2866808B1 (enExample)
JP (3) JP6258933B2 (enExample)
KR (1) KR20150023396A (enExample)
CN (1) CN104411313A (enExample)
AU (1) AU2013283281B2 (enExample)
BR (1) BR112014032555A2 (enExample)
CA (1) CA2874703C (enExample)
CL (1) CL2014003484A1 (enExample)
CO (1) CO7160087A2 (enExample)
CY (3) CY1118579T1 (enExample)
DK (3) DK2866808T3 (enExample)
EA (1) EA029908B1 (enExample)
ES (4) ES2950492T3 (enExample)
FI (1) FI3345604T3 (enExample)
HK (1) HK1255683A1 (enExample)
HR (4) HRP20230762T8 (enExample)
HU (4) HUE063313T2 (enExample)
IL (1) IL236035B (enExample)
LT (3) LT2866808T (enExample)
ME (2) ME03030B (enExample)
MX (1) MX371373B (enExample)
MY (1) MY166914A (enExample)
NZ (1) NZ702191A (enExample)
PH (1) PH12014502798A1 (enExample)
PL (4) PL3345604T3 (enExample)
PT (3) PT3345604T (enExample)
RS (2) RS57046B1 (enExample)
RU (1) RU2665373C2 (enExample)
SG (1) SG11201408704WA (enExample)
SI (3) SI3138564T1 (enExample)
SM (3) SMT201800164T1 (enExample)
UA (1) UA114199C2 (enExample)
WO (1) WO2014001427A1 (enExample)
ZA (1) ZA201409525B (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140005217A1 (en) 2012-06-27 2014-01-02 H. Lundbeck A/S Nalmefene for reduction of alcohol consumption in specific target populations
JP6419780B2 (ja) * 2013-04-17 2018-11-07 ハー・ルンドベック・アクチエゼルスカベット 睡眠障害患者の治療のためのナルメフェン
CA2946698A1 (en) 2014-04-22 2015-10-29 Otsuka Pharmaceutical Co., Ltd. Combination of brexpiprazole and nalmefene and use thereof for treating substance-related disorders
US20170071590A1 (en) * 2015-09-10 2017-03-16 Suture Armor Llc Suture anchor
KR102699603B1 (ko) 2018-04-20 2024-08-29 삼성전자주식회사 반도체 메모리 소자

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3814768A (en) 1971-11-26 1974-06-04 Lewenstein E 6-methylene-6-desoxy dihydro morphine and codeine derivatives and pharmaceutically acceptable salts
US4535157A (en) 1983-11-01 1985-08-13 Key Pharmaceuticals, Inc. Process for making 6-desoxy-6-methylenenaloxone and 6-desoxy-6-methylenenaltrexone
US5086058A (en) * 1990-06-04 1992-02-04 Alko Ltd. Method for treating alcoholism with nalmefene
EP1423116A1 (en) * 2001-08-14 2004-06-02 Biotie Therapies Corp. Method of treating alcoholism or alcohol abuse
UA102128C2 (en) * 2008-12-05 2013-06-10 Х. Луннбек А/С Nalmefene hydrochloride dihydrate
EA019331B1 (ru) 2009-05-25 2014-02-28 Х. Лундбекк А/С Получение налмефена гидрохлорида из налтрексона
AU2011325563B2 (en) 2010-11-05 2015-08-20 H. Lundbeck A/S Method for the manufacturing of naltrexone
CA2829280C (en) 2011-03-31 2016-05-24 Imuneks Farma Ilac Sanayi Ve Ticaret A.S. Compositions of opioid antagonists and their use for treating scleroderma
US20140005217A1 (en) 2012-06-27 2014-01-02 H. Lundbeck A/S Nalmefene for reduction of alcohol consumption in specific target populations

Also Published As

Publication number Publication date
ES2663532T3 (es) 2018-04-13
JP6857684B2 (ja) 2021-04-14
PL3345604T3 (pl) 2023-08-28
ES2609122T3 (es) 2017-04-18
SI3138564T1 (en) 2018-04-30
EP2866808A1 (en) 2015-05-06
RU2014151156A (ru) 2016-08-20
ME02587B (me) 2017-06-20
CY1126140T1 (el) 2023-11-15
ES3014068T3 (en) 2025-04-16
SMT201800164T1 (it) 2018-07-17
SMT201600471T1 (it) 2017-03-08
SMT201600471B (it) 2017-03-08
EA201492152A1 (ru) 2015-11-30
HRP20230762T8 (hr) 2024-01-05
MX2014015488A (es) 2015-03-06
RS55456B1 (sr) 2017-04-28
IL236035A0 (en) 2015-01-29
EP3345604A1 (en) 2018-07-11
US20140005216A1 (en) 2014-01-02
HRP20250329T1 (hr) 2025-05-09
PH12014502798A1 (en) 2015-02-09
US20160375007A1 (en) 2016-12-29
PT2866808T (pt) 2017-01-03
US9642849B2 (en) 2017-05-09
HK1255683A1 (en) 2019-08-23
EP4223296A3 (en) 2023-09-27
JP2019163275A (ja) 2019-09-26
LT2866808T (lt) 2017-01-10
CY1118579T1 (el) 2017-07-12
AU2013283281A1 (en) 2014-12-11
DK3138564T3 (en) 2018-03-26
JP2015521647A (ja) 2015-07-30
HUE063313T2 (hu) 2024-01-28
HUE031110T2 (en) 2017-06-28
EP3345604B1 (en) 2023-06-07
UA114199C2 (uk) 2017-05-10
HUE070621T2 (hu) 2025-06-28
SI3345604T1 (sl) 2023-08-31
DK2866808T3 (en) 2017-01-16
LT3138564T (lt) 2018-04-10
PL3138564T3 (pl) 2018-06-29
FI3345604T3 (fi) 2023-07-28
KR20150023396A (ko) 2015-03-05
MY166914A (en) 2018-07-24
RU2665373C2 (ru) 2018-08-29
SI2866808T1 (sl) 2017-01-31
MX371373B (es) 2020-01-28
US10034874B2 (en) 2018-07-31
CA2874703C (en) 2022-08-23
WO2014001427A1 (en) 2014-01-03
EP4541421A3 (en) 2025-06-18
JP6258933B2 (ja) 2018-01-10
US20180028526A1 (en) 2018-02-01
HUE036272T2 (hu) 2018-06-28
EP4223296A2 (en) 2023-08-09
CN104411313A (zh) 2015-03-11
CA2874703A1 (en) 2014-01-03
JP2018039810A (ja) 2018-03-15
EP4541421A2 (en) 2025-04-23
DK3345604T3 (da) 2023-07-24
US20140005217A1 (en) 2014-01-02
PL2866808T3 (pl) 2017-04-28
PT3138564T (pt) 2018-04-03
AU2013283281B2 (en) 2017-04-20
EP3138564B1 (en) 2018-01-31
RS57046B1 (sr) 2018-05-31
ES2950492T3 (es) 2023-10-10
PL4223296T3 (pl) 2025-04-14
BR112014032555A2 (pt) 2017-06-27
EA029908B1 (ru) 2018-05-31
EP3138564A1 (en) 2017-03-08
CL2014003484A1 (es) 2015-02-27
HRP20180363T1 (hr) 2018-04-20
EP4223296B1 (en) 2025-01-29
SG11201408704WA (en) 2015-01-29
IL236035B (en) 2018-12-31
HK1208185A1 (en) 2016-02-26
NZ702191A (en) 2017-06-30
HRP20230762T1 (hr) 2023-10-13
CY1120097T1 (el) 2018-12-12
LT3345604T (lt) 2023-08-10
ZA201409525B (en) 2016-08-31
PT3345604T (pt) 2023-07-17
ME03030B (me) 2018-10-20
HRP20161717T1 (hr) 2017-02-10
EP4223296C0 (en) 2025-01-29
EP2866808B1 (en) 2016-11-02

Similar Documents

Publication Publication Date Title
BR112013028643A2 (pt) sistema de dispensação de produtos com aumento de contato produto-dispensador
AR091744A1 (es) Marcadores moleculares para diversos rasgos en trigo y metodos de uso
GT201400033A (es) Pirimidinas anilladas sustituidas y uso de las mismas
ZA201507005B (en) Marker with light emitting area for use in determining vital sign information.
UY34484A (es) Benzotienilo-pirrolotriazinas disustituidas y sus usos
UY34394A (es) Polipéptidos de anticuerpos que antagonizan cd40l
MX2019009789A (es) Metodos de seleccion para microorganismos que imparten propiedades beneficiosas a las plantas.
BR112013031493A2 (pt) composto, composição farmacêutica, uso de um composto, combinação de um composto, dispositivo e processo de preparação de um composto.
ECSP13012520A (es) Proceso para la preparación de inhibidores de pan-cdk de la fórmula (i), e intermediarios de la preparación
MX2015011466A (es) Uso de linagliptina en terapia antidiabetica cardio-y renoprotectora.
MX2011007576A (es) Articulos absorbentes reusables para llevar puestos con sistema secundario de fijacion.
BR112013025866A2 (pt) formulações com viscosidade reduzida
CY1126140T1 (el) Ναλμεφενη για τη μειωση της καταναλωσεως αλκοολης σε συγκεκριμενους πληθυσμους στοχους
EA201590503A1 (ru) Альфа-1-микроглобулин для применения в лечении заболеваний, связанных с митохондриями
ES2572368T3 (es) Tratamiento de la artrosis
BR112013023253A2 (pt) método para fabricação de um artigo absorvente
BR112013007369A2 (pt) lente com parede de menisco linear de múltiplos segmentos
BR112012001487A2 (pt) dispositivo de pesquisa de informação de programa.
ES2536842T3 (es) Composición farmacéutica para el tratamiento del cáncer
BR112013023252A2 (pt) hemisfério para expansão de bexiga em pacientes com baixa tolerância
CL2015003736A1 (es) Sales de nalmefeno como medicamentos para reducir el consumo de alcohol o para prevenir el consumo excesivo de alcohol
AR077017A1 (es) Muestra fisica de un producto que cuenta con al menos un codigo de muestra del producto.
BR112012004828A2 (pt) transportador de pentose
CR20140489A (es) Uso de 18-metil-15b, 16b-metilen-19-nor-20-espirox-4-en-3-onas en el tratamiento de menorragia, y sistemas intrauterinos que comprenden 18-metil-15b, 16b-metilen-19-nor-20-espirox-4-en-3-onas para el tratamiento de t
BR112012033644A2 (pt) tapentadol para uso no tratamento de síndrome do intestino irritável

Legal Events

Date Code Title Description
FA Application withdrawn